{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:16:55Z","timestamp":1791944215770,"version":"4.3.4"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major global health concern, affecting more than one-third of the adult population worldwide. Notably, Latin America exhibits the highest regional prevalence, with recent estimates of 44.4%. This elevated burden is attributed to the convergence of risk factors that render the population particularly vulnerable. These include high rates of obesity and type 2 diabetes\n                    <jats:italic>mellitus<\/jats:italic>\n                    (T2DM), widespread adoption of energy-dense and nutrient-poor dietary patterns, low levels of physical activity, increased alcohol consumption, and underlying genetic predispositions. Despite its growing impact, MASLD remains significantly underdiagnosed in this region. This is largely due to the limited access to gold-standard diagnostic modalities, such as liver biopsy and magnetic resonance imaging, which are costly, invasive, and often unavailable in routine clinical settings. The lack of accessible diagnostic infrastructure delays early identification and intervention, contributing to disease progression and an increased healthcare burden. Consequently, there is an urgent need to establish cost-effective, non-invasive screening strategies capable of identifying individuals at risk and facilitating timely clinical decision-making. This review synthesizes the current epidemiological data on MASLD in Mexico and Latin America and examines the most validated diagnostic and screening tools currently available.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2025.1700072","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T05:40:47Z","timestamp":1769406047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Epidemiology and diagnostic of MASLD in Latin America: a yet to be met challenge"],"prefix":"10.3389","volume":"16","author":[{"given":"Carolina Elizabeth","family":"Olaez-Ramos","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, Health Sciences University Center, Universidad de Guadalajara","place":["Guadalajara, Mexico"]},{"name":"Doctorado en Ciencias en Biolog\u00eda Molecular en Medicina, Health Sciences University Center, Universidad de Guadalajara","place":["Guadalajara, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla Lizette","family":"Mojica-Zamudio","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, Health Sciences University Center, Universidad de Guadalajara","place":["Guadalajara, Mexico"]},{"name":"Doctorado en Ciencias en Biolog\u00eda Molecular en Medicina, Health Sciences University Center, Universidad de Guadalajara","place":["Guadalajara, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sandoval-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, Health Sciences University Center, Universidad de Guadalajara","place":["Guadalajara, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Armend\u00e1riz-Borunda","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, Health Sciences University Center, Universidad de Guadalajara","place":["Guadalajara, Mexico"]},{"name":"Tecnol\u00f3gico de Monterrey, EMCS","place":["Zapopan, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"B2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2021.100359","article-title":"NAFLD: challenges and opportunities to address the public health challenge in Latin America","volume":"24","author":"Arab","year":"2021","journal-title":"Ann. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1377\/hlthaff.2016.1231","article-title":"In Mexico, evidence of sustained consumer response two years after implementing a sugar-sweetened beverage tax","volume":"36","author":"Arantxa Cochero","year":"2017","journal-title":"Health Aff."},{"key":"B6","doi-asserted-by":"publisher","first-page":"s163","DOI":"10.21149\/14832","article-title":"Prevalence of prediabetes and diabetes in Mexico: ensanut 2022","volume":"65","author":"Basto-Abreu","year":"2023","journal-title":"Salud Publica Mex."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/hep.29273\/suppinfo","article-title":"The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading","volume":"66","author":"Basuray","year":"2017","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol."},{"key":"B9","unstructured":"The liver biopsy: importance and interpretation why do patients get liver biopsies?\n          \n          \n            \n              Bell\n              P.\n            \n          \n          \n          2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.rgmxen.2022.04.001","article-title":"Prevalence and clinical-epidemiologic characteristics of a Mexican population with metabolic (dysfunction) associated fatty liver disease: an open population study","volume":"88","author":"Bernal-Reyes","year":"2023","journal-title":"Rev. Gastroenterol. M\u00e9xico (English Ed.)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.3390\/diagnostics13213316","article-title":"The role of the fatty liver index (FLI) in the management of non-alcoholic fatty liver disease: a systematic review","volume":"13","author":"Biciusca","year":"2023","journal-title":"Diagn. Multidiscip. Digit. Publ. Inst. (MDPI)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12992-020-00656-2","article-title":"The political economy of sugar-sweetened beverage taxation in Latin America: lessons from Mexico, Chile and Colombia","volume":"17","author":"Carriedo","year":"2021","journal-title":"Glob. Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J. Hepatol."},{"key":"B113","volume-title":"El mundo alcanza los 8 mil millones de habitantes, de los cuales 662 millones viven en Am\u00e9rica Latina y el Caribe","year":"2022"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jamainternmed.2025.4769","article-title":"Targeting MASLD and MASH in the US Hispanic\/Latino population","volume":"185","author":"Cumpian","year":"2025","journal-title":"JAMA Intern. Med. Prepr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12986-017-0206-2","article-title":"Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults","volume":"14","author":"Dai","year":"2017","journal-title":"Nutr. Metabolism"},{"key":"B20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/diagnostics15050565","article-title":"Fatty liver index vs. biochemical\u2013anthropometric indices: diagnosing metabolic dysfunction-associated steatotic liver disease with non-invasive tools","volume":"15","author":"Demirci","year":"2025","journal-title":"Diagnostics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2025.04.035","article-title":"High inherited risk predicts age-associated increases in fibrosis in patients with MASLD","volume":"83","author":"D\u00edaz","year":"","journal-title":"J. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"101903","DOI":"10.1016\/j.aohep.2025.101903","article-title":"Updated recommendations for the management of metabolic dysfunction\u2013associated steatotic liver disease (MASLD) by the Latin American working group","volume":"30","author":"Diaz","year":"","journal-title":"Ann. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"101175","DOI":"10.1016\/j.aohep.2023.101175","article-title":"The burden of liver disease in Latin America","volume":"29","author":"D\u00edaz","year":"2024","journal-title":"Ann. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/hep.0000000000000852","article-title":"Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD practice guideline","volume":"81","author":"Duarte-Rojo","year":"2025","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12944-023-01802-6","article-title":"Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis","volume":"22","author":"Ebrahimi","year":"2023","journal-title":"Lipids Health Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatology"},{"key":"B27","volume-title":"The State of Food Security and Nutrition in the World 2023","year":"2023"},{"key":"B28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0140-6736(10)62037-5","article-title":"National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9\u00b71 million participants","volume":"377","author":"Finucane","year":"2011","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12889-016-2765-y","article-title":"Latin American study of nutrition and health (ELANS): rationale and study design","volume":"16","author":"Fisberg","year":"2016","journal-title":"BMC Public Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/medicina61040736","article-title":"Non-invasive tests as a replacement for liver biopsy in the assessment of MASLD","volume":"61","author":"Fr\u0105czek","year":"2025","journal-title":"Med. Lith. Multidiscip. Digit. Publ. Inst. (MDPI)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"s248","DOI":"10.21149\/14785","article-title":"Consumidores de grupos de alimentos en poblaci\u00f3n mexicana. Ensanut Continua 2020-2022","volume":"65","author":"Gaona-Pineda","year":"2023","journal-title":"Salud Publica Mex."},{"key":"B32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11894-012-0307-z","article-title":"Role of liver biopsy in the era of direct-acting antivirals","volume":"15","author":"Gonzalez","year":"2013","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/s40001-023-01536-2","article-title":"Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among uighurs in rural Xinjiang","volume":"28","author":"Guo","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s11739-025-03895-6","article-title":"Global burden and risk factors of MASLD: trends from 1990 to 2021 and predictions to 2030","volume":"20","author":"Huang","year":"2025","journal-title":"Intern. Emerg. Med."},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241276334","article-title":"Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: the progressive shift from liver biopsy to noninvasive techniques","volume-title":"Ther. Adv. Gastroenterol.","author":"Hudson","year":"2024"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s00535-018-1474-y","article-title":"The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study","volume":"53","author":"Ishiba","year":"2018","journal-title":"J. Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.21037\/atm-20-2951","article-title":"Development of a simple nonalcoholic fatty liver disease scoring system indicative of metabolic risks and insulin resistance","volume":"8","author":"Jeong","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2261-5-26","article-title":"The \u2018lipid accumulation product\u2019 performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison","volume":"5","author":"Kahn","year":"2005","journal-title":"BMC Cardiovasc. Disord."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.cgh.2019.02.007","article-title":"American ancestry is a risk factor for suspected nonalcoholic fatty liver disease in Hispanic\/Latino adults","volume":"17","author":"Kallwitz","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12876-023-02785-5","article-title":"Fatty liver index relationship with biomarkers and lifestyle: result from RaNCD cohort study","volume":"23","author":"Kamari","year":"2023","journal-title":"BMC Gastroenterol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American association for the study of liver diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J. Hepatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12876-023-02717-3","article-title":"CT-based hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease","volume":"23","author":"Kim","year":"2023","journal-title":"BMC Gastroenterol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease","volume":"79","author":"Kjaergaard","year":"2023","journal-title":"J. Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16123","article-title":"Global epidemiological impact of PNPLA3 I148M on liver disease","author":"Kozlitina","year":"2024","journal-title":"Liver Int."},{"key":"B47","first-page":"1470","article-title":"Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population","volume-title":"Liver International","author":"Lazo","year":"2022"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44355-024-00014-8","article-title":"Metabolic and alcohol-associated liver disease (MetALD): a representation of duality","volume":"2","author":"Leal-Lassalle","year":"2025","journal-title":"Npj Gut Liver"},{"key":"B49","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","article-title":"Natural history of metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Lekakis","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.rgmx.2020.06.011","article-title":"Dietary and sociodemographic factors associated with nonalcoholic fatty liver in obese pediatric patients","volume":"86","author":"Le\u00f3n-Plascencia","year":"2021","journal-title":"Rev. Gastroenterol. Mex."},{"key":"B53","doi-asserted-by":"publisher","first-page":"977625","DOI":"10.3389\/fendo.2022.977625","article-title":"The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults","volume":"13","author":"Li","year":"2022","journal-title":"Front. Endocrinol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1026901","DOI":"10.3389\/fendo.2022.1026901","article-title":"TM6SF2 rs58542926 is related to hepatic steatosis, fibrosis and serum lipids both in adults and children: a meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front. Endocrinol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S1665-2681(19)30879-8","article-title":"The prevalence of nonalcoholic fatty liver disease in the Americas Concise","volume":"13","author":"L\u00f3pez-Vel\u00e1zquez","year":"2014","journal-title":"Rev. Ann. Hepatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"579","DOI":"10.20524\/aog.2024.0910","article-title":"Accuracy of controlled attenuation parameter for liver steatosis in patients at risk for metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging: a systematic review and meta-analysis","volume":"37","author":"Malandris","year":"2024","journal-title":"Ann. Gastroenterol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.aohep.2018.10.004","article-title":"Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population","volume":"18","author":"Mazo","year":"2019","journal-title":"Ann. Hepatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/hep.21346","article-title":"Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease","volume":"44","author":"Merriman","year":"2006","journal-title":"Hepatology"},{"key":"B59","first-page":"697","article-title":"Current status and future trends of the global burden of MASLD","volume-title":"Trends Endocrinol. Metab.","author":"Miao","year":"2024"},{"key":"B60","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s43016-022-00594-9","article-title":"Global dietary quality in 185 countries from 1990 to 2018 show wide differences by nation, age, education, and urbanicity","volume":"3","author":"Miller","year":"2022","journal-title":"Nat. Food"},{"key":"B61","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41387-023-00237-3","article-title":"Sugar-sweetened beverages, low\/no-calorie beverages, fruit juice and non-alcoholic fatty liver disease defined by fatty liver index: the SWEET project","volume":"13","author":"Naomi","year":"2023","journal-title":"Nutr. Diabetes"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.clnu.2016.12.020","article-title":"The lipid accumulation product is a powerful tool to predict metabolic syndrome in undiagnosed Brazilian adults","volume":"36","author":"Nascimento-Ferreira","year":"2017","journal-title":"Clin. Nutr."},{"key":"B63","doi-asserted-by":"publisher","first-page":"21925","DOI":"10.1038\/s41598-022-25843-6","article-title":"Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD","volume":"12","author":"Nogami","year":"2022","journal-title":"Sci. Rep."},{"key":"B64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/diabetology6040023","article-title":"Metabolic-associated steatotic liver disease (MASLD) and type 2 diabetes: mechanisms, diagnostic approaches, and therapeutic interventions","volume":"6","author":"Ntikoudi","year":"2025","journal-title":"Diabetol. Multidiscip. Digit. Publ. Inst. (MDPI)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.7863\/jum.2012.31.7.1061","article-title":"Semiquantitative strain elastography of liver masses","volume":"31","author":"Onur","year":"2012","journal-title":"J. Ultrasound Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e0251","DOI":"10.1097\/HC9.0000000000000251","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hepatol. Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/jcdd11100316","article-title":"Lipid accumulation product is predictive of cardiovascular hospitalizations among patients with stable ischemic heart disease: long-term Follow-Up of the LAERTES study","volume":"11","author":"Papathanasiou","year":"2024","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"CD010542","DOI":"10.1002\/14651858.CD010542.pub2","article-title":"Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease","volume":"1","author":"Pavlov","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B111","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis","volume":"6","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1017\/S0007114523000028","article-title":"Prevalence of non-alcoholic fatty liver disease and its association with lifestyle habits in adults in Chile: a cross-sectional study from the national health survey 2016-2017","volume":"130","author":"Pettinelli","year":"2023","journal-title":"Br. J. Nutr."},{"key":"B70","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2214\/AJR.22.27639","article-title":"Liver fibrosis: point - ultrasound elastography is a safe, widely available, low-cost, noninvasive biomarker of liver fibrosis that is suitable for broad community use","volume":"219","author":"Pierce","year":"2022","journal-title":"Am. J. Roentgenol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1093\/hmg\/ddu121","article-title":"PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells","volume":"23","author":"Pirazzi","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/obr","article-title":"Obesity and the food system transformation in Latin America HHS public access","volume":"19","author":"Popkin","year":"2018","journal-title":"Obes. Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"102400","DOI":"10.1016\/j.clinre.2024.102400","article-title":"Diagnostic performance of sixteen biomarkers for MASLD: a study in a Mexican cohort","volume":"48","author":"Priego-Parra","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/MEG.0b013e32835f4c3d","article-title":"Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography","volume":"25","author":"Recio","year":"2013","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"","journal-title":"Hepatology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"","journal-title":"Hepatology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"B78","doi-asserted-by":"publisher","first-page":"110","DOI":"10.22551\/2025.48.1203.10322","article-title":"Beyond BMI: revealing metabolic risk in lean MASLD","volume":"12","author":"Rotaru","year":"2025","journal-title":"Archive Clin. Cases"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18525\/cu.2024.9.1.1","article-title":"Assessment of hepatic steatosis using ultrasound-based techniques: focus on fat quantification","volume":"9","author":"Rou","year":"2024","journal-title":"Clin. Ultrasound"},{"key":"B80","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.gastha.2021.12.011","article-title":"Prevalence of metabolic-associated fatty liver disease in Mexico and development of a screening tool: the MAFLD-S score","volume":"1","author":"Ruiz-Manriquez","year":"2022","journal-title":"Gastro Hep Adv."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.26633\/RPSP.2025.10","article-title":"Affordability of sugar-sweetened beverages and nonessential energy-dense foods after taxation, Mexico, 2010\u20132022","volume":"49","author":"S\u00e1nchez-Ortiz","year":"2025","journal-title":"Rev Panam Salud Publica"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.26633\/RPSP.2021.21","article-title":"Excise taxes on sugar-sweetened beverages in Latin America and the Caribbean","volume":"45","author":"Sandoval","year":"2021","journal-title":"Revista Panam. de Salud Publica\/Pan Am. J. Public Health"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"760361","DOI":"10.3389\/fcvm.2021.760361","article-title":"Relationship between the lipid accumulation product index and arterial stiffness in the Chinese population with hypertension: a report from the China H-Type hypertension registry study","volume":"8","author":"Shi","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B85","unstructured":"Global epidemiology and implications of PNPLA3 I148M variant in MASLD: a systematic review and meta-analysis\n          \n          \n            \n              Souza\n              M.\n            \n            \n              Al-Sharif\n              L.\n            \n            \n              Diaz\n              I.\n            \n            \n              Mantovani\n              A.\n            \n            \n              Villela-Nogueira\n              C. A.\n            \n          \n          10.21203\/rs.3.rs-4118917\/v1\n          \n          2024"},{"key":"B86","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12876-022-02290-1","article-title":"Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups","volume":"22","author":"Sugiyama","year":"2022","journal-title":"BMC Gastroenterol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Sumida","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e1003015","DOI":"10.1371\/JOURNAL.PMED.1003015","article-title":"An evaluation of Chile\u2019s law of food labeling and advertising on sugar-sweetened beverage purchases from 2015 to 2017: a before-and-after study","volume":"17","author":"Taillie","year":"2020","journal-title":"PLoS Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus \u2014 mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cgh.2024.06.038","article-title":"Disparities for Hispanic adults with metabolic dysfunction-associated steatotic liver disease in the United States: a systematic review and meta-analysis","volume":"23","author":"Tesfai","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1186\/s12876-025-04133-1","article-title":"Association of liver related biomarkers with incident cardiovascular disease and all-cause mortality in the Hispanic community health study\/study of Latinos (HCHS\/SOL), a population-based cohort study","volume":"25","author":"Trejo","year":"2025","journal-title":"BMC Gastroenterol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jhep.2010.07.033","article-title":"Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy","volume":"54","author":"Tsochatzis","year":"2011","journal-title":"J. Hepatol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"B98","doi-asserted-by":"publisher","first-page":"101111","DOI":"10.1016\/j.aohep.2023.101111","article-title":"Prevalence of non-alcoholic fatty liver disease and liver fibrosis in a general population cohort from Argentina","volume":"28","author":"Villamil","year":"2023","journal-title":"Ann. Hepatol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"8465371251357447","DOI":"10.1177\/08465371251357447","article-title":"Part 2: CAR metabolic dysfunction-associated steatotic liver disease working group recommendations for risk stratifying patients with MASLD","author":"Wilson","year":"2025","journal-title":"Can. Assoc. Radiol. J."},{"key":"B100","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J. Hepatol."},{"key":"B101","volume-title":"World obesity atlas 2025","year":"2025"},{"key":"B102","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1016\/j.acra.2025.03.008","article-title":"Performance of magnetic resonance imaging and ultrasound for identifying the different degrees of hepatic steatosis: a systematic review and meta-analysis","volume":"32","author":"Wu","year":"2025","journal-title":"Acad. Radiol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/ejcn.2012.83","article-title":"Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals","volume":"66","author":"Xia","year":"2012","journal-title":"Eur. J. Clin. Nutr."},{"key":"B104","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jfma.2021.07.013","article-title":"The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: a diagnostic or screening tool?","volume":"121","author":"Xu","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"B105","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12876-024-03449-8","article-title":"Evaluating the efficacy of 8 non-invasive models in predicting MASLD and progression: a prospective study","volume":"24","author":"Yang","year":"2024","journal-title":"BMC Gastroenterology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta\u2010analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jhep.2024.08.011","article-title":"Association of food insecurity with the prevalence and liver-related mortality of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"82","author":"Younossi","year":"2024","journal-title":"J. Hepatol. Prepr."},{"key":"B110","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12876-021-01675-y","article-title":"Diagnostic accuracy assessment of molecular prediction model for the risk of NAFLD based on MRI-PDFF diagnosed Chinese Han population","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Gastroenterol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1700072\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T05:40:53Z","timestamp":1769406053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1700072\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":111,"alternative-id":["10.3389\/fphar.2025.1700072"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1700072","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"article-number":"1700072"}}